David S. Millan

发表

Chapter 5:Contribution of Structure-Based Drug Design to the Discovery of Marketed drugs

Alexander Alex, David S. Millan, A. Alex, 2011 .

Fragment based discovery of a novel and selective PI3 kinase inhibitor.

David S. Millan, J. Mathias, A. Phelan, 2011, Bioorganic & medicinal chemistry letters.

Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space

Alexander Alex, David S. Millan, A. Alex, 2011 .

Consequences of Bioisosteric Replacement

David S. Millan, Dennis A. Smith, 2012 .

Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma.

David S. Millan, M. Yeadon, P. Glossop, 2011, Bioorganic & medicinal chemistry letters.

Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).

David S. Millan, Mark T. Kershaw, K. Bair, 2019, Bioorganic & medicinal chemistry letters.

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.

P. A. Bradley, Brian E Marron, Ian K Gurrell, 2017, Journal of medicinal chemistry.

Bortezomib (Velcade): A First‐in‐Class Proteasome Inhibitor

David S. Millan, Ben S Greener, 2010 .

What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?

David S. Millan, 2011, Future medicinal chemistry.

Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.

Mark E Bunnage, Samantha J Hughes, Peter G. Dodd, 2011, Journal of medicinal chemistry.

Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains.

David S. Millan, T. Herbertz, D. Cardillo, 2017, ACS medicinal chemistry letters.